• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Altamira Therapeutics Ltd (NQ: CYTO )

    0.4554 +0.0254 (+5.91%)
    Streaming Delayed Price Updated: 3:54 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 202,321
    Open 0.4400
    Bid (Size) 0.4320 (6)
    Ask (Size) 0.4950 (3)
    Prev. Close 0.4300
    Today's Range 0.4301 - 0.4998
    52wk Range 0.4000 - 17.20
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Altamira Therapeutics Provides Update on Nasdaq Listing
    From Altamira Therapeutics Ltd
    Via GlobeNewswire

    Performance

    YTD
    -86.84%
    -86.84%
    1 Month
    -26.43%
    -26.43%
    3 Month
    -54.45%
    -54.45%
    6 Month
    -69.44%
    -69.44%
    1 Year
    -91.87%
    -91.87%

    More News

    Read More
    Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Provides Business Update
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Hunting For Gains In Penny Stocks
    Via Talk Markets
    Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
    Via FinancialNewsMedia
    Topics Death
    Exposures Death
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    What's Going On With Altamira Therapeutics Stock?
    Via Benzinga
    Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
    From FN Media Group LLC
    Via GlobeNewswire
    Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
    From Altamira Therapeutics Ltd
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.